Lot B6900 is one of 7 lots of NAD+ we have release-tested for this catalogue, scored on purity, quantity, and batch traceability. Independent third-party HPLC/MS verification of this lot is available on request.
9.5/10
A+ Excellent
Purity
3.5 / 4
Quantity
4.0 / 4
Identifier
2.0 / 2
The test score is calculated from purity (how much of the vial content is the expected compound, with values closest to 100% best and below 98% considered unacceptable), quantity (how close the measured amount is to the label claim, more than plus or minus 20% is unacceptable), and identifier (whether the batch this vial came from can be traced to a certificate).
Sample details
ProductNAD+ 100mg
Sample typeSealed retail vial
Date received10 May 2026
Physical detailsPrinted label / aluminium crimp / violet cap
Test details
MethodRP-HPLC-UV + LC-MS
Tested on12 May 2026
Tested byRTT Peptides QC
ReportQC-20745
Score breakdown
Purity
99.07%
3.5 / 4
Measured purity by RP-HPLC-UV against the ≥ 98.0% release specification. Net peptide content 90.2%.
Quantity
96.5mg
4.0 / 4
Label claim 100mg, measured 96.5mg, divergence -3.5%. Within plus or minus 5% of label scores full marks.
Identifier
B6900
2.0 / 2
Batch identifier printed on the vial and traceable to this certificate, so the lot can be verified end to end.
Sample logistics
04 May 2026
Sample logged for release testing
10 May 2026
Received and processed at the QC facility
12 May 2026
Assayed by RP-HPLC-UV with LC-MS confirmation
13 May 2026
Certificate of analysis issued and released
Certificate authentication
Test certificate ID1n0npx5
ProductNAD+ 100mg from RTT Peptides
Batch IDB6900
Tested byRTT Peptides QC on 12 May 2026
Verification URL
https://www.rttpeptides.ca/verify/coa/nad-B6900/
Detailed certificate of analysis
RTT PEPTIDES · QUALITY ASSURANCE
Analytical release certificate · RP-HPLC-UV with LC-MS confirmation Independent third-party verification available on request.
ReportQC-20745Issued2026-05-13Page1 of 1
Certificate of Analysis
NAD+ · Lot B6900
SampleNAD+
Issued forRTT Peptides
Lot / BatchB6900
Label claim100mg
CASN/A
AppearanceWhite lyophilised powder
Date received2026-05-10
Date analysed2026-05-12
01 Purity by RP-HPLC-UV
Figure 1 · Reverse-phase HPLC-UV chromatogram at 214 nm. C18, 2.7 µm; gradient 0.1% TFA in water / acetonitrile at 1.0 mL/min.
Purity by RP-HPLC-UV: component retention time, peak area, and area percent
#
Component
RT (min)
Area (mAU·s)
Area %
1
RRT 0.87
8.83
13.0
0.31
2
NAD+ ▸ main
10.14
4160.9
99.07
3
RRT 1.38
14.02
26.0
0.62
✓
Purity (HPLC) 99.07% · net peptide content 90.2% · meets the ≥ 98.0% release specification.
02 Identity by LC-MS
Expected average massper structure
Observed massconsistent
✓
Identity confirmed · observed mass conforms to the expected structure of NAD+.
03 Summary of results
Summary of results: test, method, specification, result, and outcome
Test
Method
Specification
Result
Outcome
Purity
RP-HPLC-UV, 214 nm
≥ 98.0 %
99.07 %
✓ Pass
Identity
LC-MS (ESI+)
Consistent with structure
Confirmed
✓ Pass
Net peptide content
By difference
Report
90.2 %
n/a
Appearance
Visual
White lyophilised powder
Conforms
✓ Pass
Reconstitution
Bacteriostatic water
Clear, particulate-free
Conforms
✓ Pass
The submitted lot conforms to identity and meets the stated purity specification. Analysis was performed by RP-HPLC-UV with LC-MS confirmation. Results relate only to the lot as received and tested and do not constitute a certificate of any third party.
Quality Assurance · RTT Peptides
Issued under the RTT Peptides quality programme; this is the vendor's own release certificate. Independent third-party HPLC/MS verification of any lot is available on request. Products are supplied strictly as research reagents for in-vitro laboratory use only, not for human or animal consumption. Report QC-20745 · RP.
This is the vendor's own release certificate. Independent third-party HPLC/MS verification of this lot is available on request.
Research use only
RTT Peptides sells laboratory research reagents. They are not for human or animal consumption. Please confirm before entering.
